FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely andrology and may be used for correction of hyperestradiolemia and normogonadotropic hypogonadism in males. That is ensured by the aramotase blocker Letrosol in a dose individually prescribed by the blood estradiol and testosterone level. The invention provides reducing a level of estrogens ensures by blocking their synthesis from androgens, increasing a testosterone level due to blocking its aromatisation with Letrosol and stimulating by gonadotropin development.
EFFECT: as a consequence of the growing blood testosterone level and the reduced blood estradiol level ensures improved libido, normalised erection and higher sperm fertility.
2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CORRECTION OF ERECTILE DYSFUNCTION CAUSED BY HYPERESTRADIOLEMIA IN MEN | 2014 |
|
RU2582273C1 |
| METHOD OF TREATING HYPOGONADOTROPIC HYPOGONADISM, NASAL SPRAY AS METHOD FOR ADMINISTERING GONADORELIN ACETATE IN TREATING HYPOGONADOTROPIC HYPOGONADISM | 2019 |
|
RU2733465C1 |
| APPLICATION OF AROMATASE INHIBITOR FOR TREATMENT OF HYPOGONADISM AND RELATED DISEASES | 2012 |
|
RU2628808C2 |
| DIAGNOSTIC TECHNIQUE FOR HORMONAL DISORDERS IN MEN | 2019 |
|
RU2715565C1 |
| METHODS AND MATERIALS FOR TREATING TESTOSTERONE FAILURE IN MEN | 2002 |
|
RU2297218C2 |
| METHOD FOR PREDICTING THE MANIFESTATION OF HYPOGONADISM IN MEN | 2022 |
|
RU2786597C1 |
| METHOD FOR AROMATASE ACTIVITY TEST | 2012 |
|
RU2481587C1 |
| METHOD FOR ASSESSING OVARIAN AROMATASE ACTIVITY | 2013 |
|
RU2549491C1 |
| METHOD FOR TREATING MALE PATIENTS FOR ERECTILE DYSFUNCTION AND HIGH LIBIDO | 2001 |
|
RU2303981C2 |
| METHOD FOR PREDICTION OF EFFECTIVENESS OF AROMATASE INHIBITORS IN TREATING IDIOPATHIC STERILITY IN MALES SUFFERING OBESITY | 2012 |
|
RU2503008C1 |
